Mr Christopher J Steller, LICSW | |
8737 County Rd, Calais, VT 05648-7511 | |
(802) 223-3867 | |
Not Available |
Full Name | Mr Christopher J Steller |
---|---|
Gender | Male |
Speciality | Clinical Social Worker |
Experience | 29 Years |
Location | 8737 County Rd, Calais, Vermont |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1295876266 | NPI | - | NPPES |
61809 | Other | VT | MVP PROVIDER NUMBER |
1047412 | Other | VT | CIGNA PROVIDER # |
29987 | Other | VT | BCBS PROVIDER NUMBER |
OVN2208 | Medicaid | VT |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | 089-0000651 (Vermont) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Christopher J Steller, LICSW 8737 County Rd, Calais, VT 05648-7511 Ph: (802) 223-3867 | Mr Christopher J Steller, LICSW 8737 County Rd, Calais, VT 05648-7511 Ph: (802) 223-3867 |
News Archive
Incorporating high-intensity interval training, or HIIT, into exercise programs for individuals with Down syndrome may help achieve critical health outcomes in a more time-efficient manner, according to an article written by researchers at the University of Georgia and Kennesaw State University.
Leading medical journal The Lancet has rubbished homeopathy and says it is no more value than dummy drugs.
In a recent edition of VOA News' "Science In The News," correspondents Bob Doughty and Shirley Griffith report on "the growing use of generic drugs in fighting HIV" and discuss "the search for an effective vaccine against HIV."
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that in the treatment of dyslipidemia, surveyed cardiologists and primary care physicians (PCPs) now perceive AstraZeneca's Crestor's ability to reduce mortality comparable to Pfizer's Lipitor. This finding has changed from Decision Resources' 2009 analysis in which surveyed cardiologists viewed Lipitor as significantly better on this end point.
› Verified 8 days ago